nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—Behcet's disease	0.837	1	CbGaD
Thalidomide—Pomalidomide—TNF—Behcet's disease	0.00584	1	CrCbGaD
Thalidomide—NFKB1—mouth—Behcet's disease	0.00429	0.0679	CbGeAlD
Thalidomide—FGFR2—mouth—Behcet's disease	0.00322	0.051	CbGeAlD
Thalidomide—NFKB1—eye—Behcet's disease	0.00273	0.0432	CbGeAlD
Thalidomide—CRBN—retina—Behcet's disease	0.00226	0.0359	CbGeAlD
Thalidomide—NFKB1—mammalian vulva—Behcet's disease	0.00216	0.0343	CbGeAlD
Thalidomide—FGFR2—brainstem—Behcet's disease	0.0021	0.0333	CbGeAlD
Thalidomide—NFKB1—cardiac atrium—Behcet's disease	0.00207	0.0328	CbGeAlD
Thalidomide—FGFR2—eye—Behcet's disease	0.00205	0.0324	CbGeAlD
Thalidomide—TNF—amb2 Integrin signaling—ITGB2—Behcet's disease	0.00202	0.0215	CbGpPWpGaD
Thalidomide—CRBN—mammalian vulva—Behcet's disease	0.00181	0.0287	CbGeAlD
Thalidomide—FGFR2—skin of body—Behcet's disease	0.00178	0.0282	CbGeAlD
Thalidomide—NFKB1—T-Cell Receptor and Co-stimulatory Signaling—CTLA4—Behcet's disease	0.00178	0.019	CbGpPWpGaD
Thalidomide—CRBN—cardiac atrium—Behcet's disease	0.00174	0.0275	CbGeAlD
Thalidomide—TNF—IL27-mediated signaling events—STAT4—Behcet's disease	0.00172	0.0183	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—STAT4—Behcet's disease	0.0017	0.0181	CbGpPWpGaD
Thalidomide—CRBN—medulla oblongata—Behcet's disease	0.00164	0.0259	CbGeAlD
Thalidomide—PTGS1—artery—Behcet's disease	0.00157	0.0249	CbGeAlD
Thalidomide—PTGS2—artery—Behcet's disease	0.0015	0.0238	CbGeAlD
Thalidomide—CRBN—midbrain—Behcet's disease	0.0015	0.0237	CbGeAlD
Thalidomide—NFKB1—nervous system—Behcet's disease	0.00147	0.0232	CbGeAlD
Thalidomide—CRBN—spinal cord—Behcet's disease	0.00146	0.0231	CbGeAlD
Thalidomide—NFKB1—Oxidative Stress—CAT—Behcet's disease	0.00143	0.0152	CbGpPWpGaD
Thalidomide—NFKB1—central nervous system—Behcet's disease	0.00141	0.0224	CbGeAlD
Thalidomide—NFKB1—TSLP Signaling Pathway—STAT4—Behcet's disease	0.0014	0.015	CbGpPWpGaD
Thalidomide—PTGS1—endothelium—Behcet's disease	0.00133	0.021	CbGeAlD
Thalidomide—NFKB1—amb2 Integrin signaling—APOB—Behcet's disease	0.00131	0.014	CbGpPWpGaD
Thalidomide—FGFR2—spinal cord—Behcet's disease	0.00131	0.0207	CbGeAlD
Thalidomide—TNF—IL23-mediated signaling events—STAT4—Behcet's disease	0.0013	0.0138	CbGpPWpGaD
Thalidomide—PTGS2—endothelium—Behcet's disease	0.00127	0.0201	CbGeAlD
Thalidomide—NFKB1—IL1 and megakaryotyces in obesity—ICAM1—Behcet's disease	0.00124	0.0133	CbGpPWpGaD
Thalidomide—CRBN—nervous system—Behcet's disease	0.00123	0.0195	CbGeAlD
Thalidomide—PTGS1—blood vessel—Behcet's disease	0.00122	0.0194	CbGeAlD
Thalidomide—CRBN—central nervous system—Behcet's disease	0.00118	0.0188	CbGeAlD
Thalidomide—PTGS2—blood vessel—Behcet's disease	0.00117	0.0185	CbGeAlD
Thalidomide—CYP1A1—mouth—Behcet's disease	0.00116	0.0185	CbGeAlD
Thalidomide—NFKB1—IL12-mediated signaling events—STAT4—Behcet's disease	0.00116	0.0123	CbGpPWpGaD
Thalidomide—NFKB1—brain—Behcet's disease	0.00112	0.0178	CbGeAlD
Thalidomide—TNF—Cytokines and Inflammatory Response—IL10—Behcet's disease	0.00112	0.0119	CbGpPWpGaD
Thalidomide—FGFR2—nervous system—Behcet's disease	0.0011	0.0175	CbGeAlD
Thalidomide—FGFR2—central nervous system—Behcet's disease	0.00106	0.0168	CbGeAlD
Thalidomide—TNF—amb2 Integrin signaling—APOB—Behcet's disease	0.001	0.0107	CbGpPWpGaD
Thalidomide—NFKB1—amb2 Integrin signaling—ICAM1—Behcet's disease	0.000988	0.0105	CbGpPWpGaD
Thalidomide—PTGS2—mouth—Behcet's disease	0.000978	0.0155	CbGeAlD
Thalidomide—FGFR2—Angiogenesis—NOS3—Behcet's disease	0.000942	0.01	CbGpPWpGaD
Thalidomide—CRBN—brain—Behcet's disease	0.00094	0.0149	CbGeAlD
Thalidomide—NFKB1—EBV LMP1 signaling—CXCL8—Behcet's disease	0.000911	0.0097	CbGpPWpGaD
Thalidomide—NFKB1—Toll Like Receptor 4 (TLR4) Cascade—ITGB2—Behcet's disease	0.000908	0.00968	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—APOB—Behcet's disease	0.000906	0.00965	CbGpPWpGaD
Thalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—CAT—Behcet's disease	0.000899	0.00958	CbGpPWpGaD
Thalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—Behcet's disease	0.000877	0.00934	CbGpPWpGaD
Thalidomide—FGFR2—brain—Behcet's disease	0.000842	0.0133	CbGeAlD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—STAT4—Behcet's disease	0.000816	0.00869	CbGpPWpGaD
Thalidomide—NFKB1—Toll-Like Receptors Cascades—ITGB2—Behcet's disease	0.000809	0.00862	CbGpPWpGaD
Thalidomide—TNF—Overview of nanoparticle effects—CXCL8—Behcet's disease	0.000809	0.00861	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—CAT—Behcet's disease	0.000759	0.00809	CbGpPWpGaD
Thalidomide—TNF—amb2 Integrin signaling—ICAM1—Behcet's disease	0.000753	0.00802	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—APOB—Behcet's disease	0.000737	0.00785	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—APOA1—Behcet's disease	0.000717	0.00763	CbGpPWpGaD
Thalidomide—TNF—EBV LMP1 signaling—CXCL8—Behcet's disease	0.000694	0.00739	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—APOB—Behcet's disease	0.00069	0.00735	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—ICAM1—Behcet's disease	0.000681	0.00725	CbGpPWpGaD
Thalidomide—CYP1A1—skin of body—Behcet's disease	0.000645	0.0102	CbGeAlD
Thalidomide—NFKB1—RANKL/RANK Signaling Pathway—ICAM1—Behcet's disease	0.000641	0.00683	CbGpPWpGaD
Thalidomide—NFKB1—EBV LMP1 signaling—TNF—Behcet's disease	0.000634	0.00675	CbGpPWpGaD
Thalidomide—NFKB1—Canonical NF-kappaB pathway—TNF—Behcet's disease	0.000634	0.00675	CbGpPWpGaD
Thalidomide—PTGS1—Overview of nanoparticle effects—CXCL8—Behcet's disease	0.00063	0.00671	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—CTLA4—Behcet's disease	0.000608	0.00648	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—CAT—Behcet's disease	0.000603	0.00642	CbGpPWpGaD
Thalidomide—CYP1A1—Oxidative Stress—CAT—Behcet's disease	0.000596	0.00635	CbGpPWpGaD
Thalidomide—CYP1A1—mammalian vulva—Behcet's disease	0.000588	0.00932	CbGeAlD
Thalidomide—NFKB1—Selenium Micronutrient Network—APOB—Behcet's disease	0.000585	0.00624	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—APOA1—Behcet's disease	0.000583	0.00621	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—CAT—Behcet's disease	0.000578	0.00616	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—SERPINE1—Behcet's disease	0.000569	0.00606	CbGpPWpGaD
Thalidomide—PTGS1—skin of body—Behcet's disease	0.000566	0.00897	CbGeAlD
Thalidomide—CYP1A1—cardiac atrium—Behcet's disease	0.000563	0.00892	CbGeAlD
Thalidomide—TNF—Folate Metabolism—APOB—Behcet's disease	0.000561	0.00598	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—ICAM1—Behcet's disease	0.000554	0.0059	CbGpPWpGaD
Thalidomide—NFKB1—Angiopoietin receptor Tie2-mediated signaling—NOS3—Behcet's disease	0.000552	0.00588	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—APOA1—Behcet's disease	0.000546	0.00582	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—SERPINE1—Behcet's disease	0.000543	0.00579	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—Behcet's disease	0.000542	0.00578	CbGpPWpGaD
Thalidomide—PTGS2—skin of body—Behcet's disease	0.000541	0.00858	CbGeAlD
Thalidomide—TNF—Vitamin B12 Metabolism—ICAM1—Behcet's disease	0.000519	0.00553	CbGpPWpGaD
Thalidomide—PTGS1—mammalian vulva—Behcet's disease	0.000516	0.00818	CbGeAlD
Thalidomide—NFKB1—TSLP Signaling Pathway—CXCL8—Behcet's disease	0.000514	0.00548	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—CAT—Behcet's disease	0.000508	0.00541	CbGpPWpGaD
Thalidomide—PTGS2—Overview of nanoparticle effects—CXCL8—Behcet's disease	0.0005	0.00533	CbGpPWpGaD
Thalidomide—PTGS1—cardiac atrium—Behcet's disease	0.000495	0.00784	CbGeAlD
Thalidomide—NFKB1—amb2 Integrin signaling—TNF—Behcet's disease	0.000487	0.00519	CbGpPWpGaD
Thalidomide—CYP2E1—medulla oblongata—Behcet's disease	0.000484	0.00767	CbGeAlD
Thalidomide—NFKB1—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—Behcet's disease	0.000475	0.00506	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL10—Behcet's disease	0.000473	0.00504	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—SERPINE1—Behcet's disease	0.000468	0.00499	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—ICAM1—Behcet's disease	0.000466	0.00496	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—APOA1—Behcet's disease	0.000463	0.00493	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—SERPINE1—Behcet's disease	0.000463	0.00493	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—CAT—Behcet's disease	0.000459	0.00489	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-B—Behcet's disease	0.00045	0.00479	CbGpPWpGaD
Thalidomide—CYP2E1—Tryptophan metabolism—CAT—Behcet's disease	0.000449	0.00479	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—APOB—Behcet's disease	0.000446	0.00475	CbGpPWpGaD
Thalidomide—PTGS2—medulla oblongata—Behcet's disease	0.000446	0.00706	CbGeAlD
Thalidomide—TNF—Folate Metabolism—APOA1—Behcet's disease	0.000444	0.00473	CbGpPWpGaD
Thalidomide—NFKB1—AGE/RAGE pathway—NOS3—Behcet's disease	0.000442	0.00471	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—ICAM1—Behcet's disease	0.00044	0.00469	CbGpPWpGaD
Thalidomide—PTGS1—Overview of nanoparticle effects—TNF—Behcet's disease	0.000438	0.00467	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—TNF—Behcet's disease	0.000433	0.00462	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—SERPINE1—Behcet's disease	0.000433	0.00462	CbGpPWpGaD
Thalidomide—CYP2E1—spinal cord—Behcet's disease	0.000432	0.00684	CbGeAlD
Thalidomide—CYP1A1—Tryptophan metabolism—CAT—Behcet's disease	0.000424	0.00451	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—ICAM1—Behcet's disease	0.000422	0.0045	CbGpPWpGaD
Thalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—NOS3—Behcet's disease	0.00042	0.00448	CbGpPWpGaD
Thalidomide—PTGS1—spinal cord—Behcet's disease	0.000416	0.00659	CbGeAlD
Thalidomide—TNF—TGF-beta Receptor Signaling—SERPINE1—Behcet's disease	0.000414	0.00441	CbGpPWpGaD
Thalidomide—PTGS2—midbrain—Behcet's disease	0.000407	0.00645	CbGeAlD
Thalidomide—NFKB1—LPA receptor mediated events—CXCL8—Behcet's disease	0.000402	0.00428	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—NOS3—Behcet's disease	0.000399	0.00425	CbGpPWpGaD
Thalidomide—CYP1A1—nervous system—Behcet's disease	0.000399	0.00632	CbGeAlD
Thalidomide—NFKB1—Innate Immune System—MEFV—Behcet's disease	0.000397	0.00423	CbGpPWpGaD
Thalidomide—PTGS2—spinal cord—Behcet's disease	0.000397	0.0063	CbGeAlD
Thalidomide—NFKB1—TWEAK Signaling Pathway—TNF—Behcet's disease	0.000392	0.00417	CbGpPWpGaD
Thalidomide—CYP1A1—central nervous system—Behcet's disease	0.000384	0.00608	CbGeAlD
Thalidomide—FGFR2—Innate Immune System—MEFV—Behcet's disease	0.000377	0.00402	CbGpPWpGaD
Thalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—Behcet's disease	0.000373	0.00397	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—SERPINE1—Behcet's disease	0.000368	0.00392	CbGpPWpGaD
Thalidomide—NFKB1—TNF receptor signaling pathway —TNF—Behcet's disease	0.000364	0.00388	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—TNF—Behcet's disease	0.000364	0.00388	CbGpPWpGaD
Thalidomide—CYP2E1—nervous system—Behcet's disease	0.000364	0.00576	CbGeAlD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL10—Behcet's disease	0.00036	0.00384	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—CAT—Behcet's disease	0.000358	0.00381	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—APOA1—Behcet's disease	0.000353	0.00376	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—SERPINE1—Behcet's disease	0.000353	0.00376	CbGpPWpGaD
Thalidomide—NFKB1—Ceramide signaling pathway—TNF—Behcet's disease	0.000352	0.00375	CbGpPWpGaD
Thalidomide—PTGS1—nervous system—Behcet's disease	0.00035	0.00555	CbGeAlD
Thalidomide—CYP2E1—central nervous system—Behcet's disease	0.00035	0.00555	CbGeAlD
Thalidomide—PTGS2—Overview of nanoparticle effects—TNF—Behcet's disease	0.000348	0.00371	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—APOB—Behcet's disease	0.000347	0.0037	CbGpPWpGaD
Thalidomide—NFKB1—Angiopoietin receptor Tie2-mediated signaling—TNF—Behcet's disease	0.000341	0.00363	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ERAP1—Behcet's disease	0.00034	0.00362	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—NOS3—Behcet's disease	0.000339	0.00361	CbGpPWpGaD
Thalidomide—PTGS1—central nervous system—Behcet's disease	0.000337	0.00534	CbGeAlD
Thalidomide—NFKB1—Vitamin B12 Metabolism—TNF—Behcet's disease	0.000335	0.00357	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—ICAM1—Behcet's disease	0.000335	0.00357	CbGpPWpGaD
Thalidomide—PTGS2—nervous system—Behcet's disease	0.000335	0.00531	CbGeAlD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—CXCL8—Behcet's disease	0.000329	0.00351	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—Behcet's disease	0.000325	0.00346	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ERAP1—Behcet's disease	0.000323	0.00344	CbGpPWpGaD
Thalidomide—PTGS2—central nervous system—Behcet's disease	0.000322	0.00511	CbGeAlD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—TNF—Behcet's disease	0.00032	0.00341	CbGpPWpGaD
Thalidomide—NFKB1—Cardiac Hypertrophic Response—TNF—Behcet's disease	0.000316	0.00336	CbGpPWpGaD
Thalidomide—CYP1A1—brain—Behcet's disease	0.000305	0.00483	CbGeAlD
Thalidomide—NFKB1—Corticotropin-releasing hormone—CXCL8—Behcet's disease	0.0003	0.0032	CbGpPWpGaD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—TNF—Behcet's disease	0.000299	0.00319	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HLA-B—Behcet's disease	0.000294	0.00313	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—CAT—Behcet's disease	0.000284	0.00303	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—SERPINE1—Behcet's disease	0.00028	0.00298	CbGpPWpGaD
Thalidomide—CYP2E1—brain—Behcet's disease	0.000278	0.0044	CbGeAlD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—CXCL8—Behcet's disease	0.000277	0.00295	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—APOB—Behcet's disease	0.000276	0.00294	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—APOA1—Behcet's disease	0.000275	0.00293	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL10—Behcet's disease	0.000274	0.00292	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—TNF—Behcet's disease	0.000273	0.00291	CbGpPWpGaD
Thalidomide—NFKB1—Senescence-Associated Secretory Phenotype (SASP)—CXCL8—Behcet's disease	0.00027	0.00288	CbGpPWpGaD
Thalidomide—CYP1A2—Tryptophan metabolism—CAT—Behcet's disease	0.00027	0.00288	CbGpPWpGaD
Thalidomide—PTGS1—brain—Behcet's disease	0.000268	0.00424	CbGeAlD
Thalidomide—TNF—Spinal Cord Injury—ICAM1—Behcet's disease	0.000265	0.00282	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—ITGB2—Behcet's disease	0.000262	0.00279	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—ICAM1—Behcet's disease	0.000261	0.00278	CbGpPWpGaD
Thalidomide—NFKB1—Signaling events mediated by HDAC Class I—TNF—Behcet's disease	0.00026	0.00277	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—CXCL8—Behcet's disease	0.000259	0.00275	CbGpPWpGaD
Thalidomide—PTGS2—brain—Behcet's disease	0.000256	0.00406	CbGeAlD
Thalidomide—NFKB1—Adaptive Immune System—ITGB2—Behcet's disease	0.000252	0.00268	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—CAT—Behcet's disease	0.00025	0.00267	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—ITGB2—Behcet's disease	0.000249	0.00265	CbGpPWpGaD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—TNF—Behcet's disease	0.000241	0.00257	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ITGB2—Behcet's disease	0.000239	0.00254	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MEFV—Behcet's disease	0.000231	0.00247	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—Behcet's disease	0.000231	0.00246	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ITGAL—Behcet's disease	0.000227	0.00242	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TNF—Behcet's disease	0.000225	0.0024	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—TNF—Behcet's disease	0.000225	0.0024	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—NOS3—Behcet's disease	0.000223	0.00238	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MEFV—Behcet's disease	0.00022	0.00234	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—APOA1—Behcet's disease	0.000218	0.00232	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—SERPINE1—Behcet's disease	0.000218	0.00232	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—TNF—Behcet's disease	0.000217	0.00231	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—CXCL8—Behcet's disease	0.000216	0.0023	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ITGAL—Behcet's disease	0.000215	0.00229	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-B—Behcet's disease	0.000215	0.00229	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TNF—Behcet's disease	0.000213	0.00227	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—CXCL8—Behcet's disease	0.000211	0.00225	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—TNF—Behcet's disease	0.000209	0.00223	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—ICAM1—Behcet's disease	0.000207	0.00221	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERAP1—Behcet's disease	0.000206	0.0022	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—SERPINE1—Behcet's disease	0.000205	0.00218	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—CXCL8—Behcet's disease	0.000197	0.0021	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERAP1—Behcet's disease	0.000196	0.00209	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—TNF—Behcet's disease	0.000193	0.00205	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—CXCL8—Behcet's disease	0.000188	0.002	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—ICAM1—Behcet's disease	0.000174	0.00186	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—SERPINE1—Behcet's disease	0.000173	0.00185	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—Behcet's disease	0.000172	0.00183	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—CXCL8—Behcet's disease	0.000171	0.00182	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—CXCL8—Behcet's disease	0.000165	0.00175	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—ICAM1—Behcet's disease	0.000164	0.00175	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—APOA1—Behcet's disease	0.000162	0.00173	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Behcet's disease	0.000161	0.00171	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—APOA1—Behcet's disease	0.000159	0.00169	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CTLA4—Behcet's disease	0.000156	0.00166	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ITGB2—Behcet's disease	0.000153	0.00163	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—TNF—Behcet's disease	0.000152	0.00162	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—Behcet's disease	0.000152	0.00162	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—TNF—Behcet's disease	0.00015	0.0016	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—CXCL8—Behcet's disease	0.00015	0.0016	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CTLA4—Behcet's disease	0.000148	0.00158	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ITGB2—Behcet's disease	0.000145	0.00154	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ITGAL—Behcet's disease	0.000138	0.00147	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TNF—Behcet's disease	0.000137	0.00146	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ITGAL—Behcet's disease	0.000131	0.00139	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—CXCL8—Behcet's disease	0.000129	0.00138	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TNF—Behcet's disease	0.000129	0.00138	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—TNF—Behcet's disease	0.000129	0.00137	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HLA-B—Behcet's disease	0.00012	0.00128	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—Behcet's disease	0.000117	0.00124	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—CXCL8—Behcet's disease	0.000116	0.00124	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-B—Behcet's disease	0.000116	0.00123	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HLA-B—Behcet's disease	0.000114	0.00122	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-B—Behcet's disease	0.00011	0.00117	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—APOA1—Behcet's disease	0.000109	0.00116	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCR1—Behcet's disease	0.000104	0.00111	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—Behcet's disease	0.000102	0.00109	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCR1—Behcet's disease	9.84e-05	0.00105	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Behcet's disease	9.71e-05	0.00103	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Behcet's disease	9.71e-05	0.00103	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CTLA4—Behcet's disease	9.47e-05	0.00101	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ICAM1—Behcet's disease	9.39e-05	0.001	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CTLA4—Behcet's disease	8.99e-05	0.000958	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ICAM1—Behcet's disease	8.91e-05	0.000949	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—Behcet's disease	8.08e-05	0.00086	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—APOB—Behcet's disease	7.81e-05	0.000831	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-B—Behcet's disease	7.01e-05	0.000746	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-B—Behcet's disease	6.65e-05	0.000708	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APOB—Behcet's disease	6.63e-05	0.000707	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOB—Behcet's disease	6.2e-05	0.00066	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—APOA1—Behcet's disease	6.18e-05	0.000658	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ICAM1—Behcet's disease	5.69e-05	0.000607	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—APOB—Behcet's disease	5.5e-05	0.000586	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—Behcet's disease	5.49e-05	0.000585	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—Behcet's disease	5.45e-05	0.000581	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ICAM1—Behcet's disease	5.4e-05	0.000575	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APOA1—Behcet's disease	5.25e-05	0.000559	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOA1—Behcet's disease	4.9e-05	0.000522	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOB—Behcet's disease	4.9e-05	0.000522	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOB—Behcet's disease	4.65e-05	0.000495	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOB—Behcet's disease	4.5e-05	0.000479	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—APOA1—Behcet's disease	4.35e-05	0.000463	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SERPINE1—Behcet's disease	4.17e-05	0.000444	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOB—Behcet's disease	4.1e-05	0.000437	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS3—Behcet's disease	3.98e-05	0.000424	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOA1—Behcet's disease	3.87e-05	0.000413	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOA1—Behcet's disease	3.68e-05	0.000392	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CAT—Behcet's disease	3.58e-05	0.000381	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—Behcet's disease	3.56e-05	0.000379	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOB—Behcet's disease	3.51e-05	0.000374	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOB—Behcet's disease	3.48e-05	0.00037	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOB—Behcet's disease	3.29e-05	0.000351	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—Behcet's disease	3.25e-05	0.000346	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SERPINE1—Behcet's disease	3.08e-05	0.000328	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOS3—Behcet's disease	2.94e-05	0.000313	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SERPINE1—Behcet's disease	2.92e-05	0.000311	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CAT—Behcet's disease	2.84e-05	0.000303	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOS3—Behcet's disease	2.79e-05	0.000297	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—Behcet's disease	2.77e-05	0.000296	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOB—Behcet's disease	2.76e-05	0.000294	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOA1—Behcet's disease	2.75e-05	0.000293	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CAT—Behcet's disease	2.68e-05	0.000285	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAT—Behcet's disease	2.67e-05	0.000284	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOA1—Behcet's disease	2.61e-05	0.000278	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL8—Behcet's disease	2.6e-05	0.000277	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOB—Behcet's disease	2.6e-05	0.000277	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOB—Behcet's disease	2.59e-05	0.000276	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAT—Behcet's disease	2.52e-05	0.000269	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL8—Behcet's disease	2.47e-05	0.000263	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOB—Behcet's disease	2.45e-05	0.000261	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOA1—Behcet's disease	2.18e-05	0.000233	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—Behcet's disease	2.08e-05	0.000222	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—Behcet's disease	2.07e-05	0.00022	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAT—Behcet's disease	2.06e-05	0.00022	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOA1—Behcet's disease	2.06e-05	0.000219	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOA1—Behcet's disease	2.05e-05	0.000218	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOB—Behcet's disease	2e-05	0.000213	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—Behcet's disease	1.98e-05	0.00021	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOA1—Behcet's disease	1.94e-05	0.000206	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAT—Behcet's disease	1.88e-05	0.000201	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOB—Behcet's disease	1.83e-05	0.000195	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—Behcet's disease	1.65e-05	0.000176	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAT—Behcet's disease	1.61e-05	0.000171	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOA1—Behcet's disease	1.59e-05	0.000169	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOB—Behcet's disease	1.56e-05	0.000166	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—Behcet's disease	1.56e-05	0.000166	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—Behcet's disease	1.55e-05	0.000166	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—Behcet's disease	1.47e-05	0.000156	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOA1—Behcet's disease	1.45e-05	0.000154	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOA1—Behcet's disease	1.24e-05	0.000132	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—Behcet's disease	1.2e-05	0.000128	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—Behcet's disease	1.1e-05	0.000117	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—Behcet's disease	9.36e-06	9.97e-05	CbGpPWpGaD
